We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SR Pharma PLC reported annual losses little changed on last year and predicted a slew of deals in the coming months as it focuses on building a presence in new RNAi technology, which is used to identify and development novel therapeutics for drug makers.
Iconix Pharmaceuticals, Inc. today announced that a study by Iconix scientists on the use of genomic data to find biomarkers to predict adverse effects of drug candidates has received the "Best Paper of 2005" award from the well known industry journal Toxicologic Pathology
Sirion Therapeutics, Inc., an ophthalmic-focused pharmaceutical company, announced today that it has reached an exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. of Japan for the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases.
Florida Atlantic University announced today an exclusive license agreement with CHS Resources LLC for a novel cancer therapy which has emerged from its Center of Excellence in Biomedical and Marine Biotechnology.
Drugmakers are only urged -- not obligated -- to remove error-prone medical abbreviations from labeling, advertising and packaging under the FDA's new campaign to purge these abbreviations from all forms of medical communication.
Vintage Pharmaceuticals, a generic drug manufacturer, has pleaded guilty to felony charges of distributing adulterated drugs through interstate commerce.
Any legislative fix to the current FDA approval process for follow-on biologics is likely at least two years away because of other legislative priorities and the need for lawmakers to get up to speed on this issue, a Senate staffer says.